In contrast to the majority of phase III trial data [6,7,8,9,10,11,12], in our NSCLC cohort, the PD-L1 expression on tumor cells was not associated with OS (Figure S2B). This evidence concerns the gene CD274 and non-small cell lung carcinoma.